Cargando…

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis

Accumulating evidence supports the early use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose transporter-2 inhibitors (SGLT-2is) for the treatment of type 2 diabetes. Indeed, these compounds exert numerous pleiotropic actions that favorably affect metabolism and diabetes c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cignarelli, Angelo, Genchi, Valentina Annamaria, Le Grazie, Giulia, Caruso, Irene, Marrano, Nicola, Biondi, Giuseppina, D’Oria, Rossella, Sorice, Gian Pio, Natalicchio, Annalisa, Perrini, Sebastio, Laviola, Luigi, Giorgino, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899086/ https://www.ncbi.nlm.nih.gov/pubmed/35265043 http://dx.doi.org/10.3389/fendo.2022.846903

Ejemplares similares

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
por: Caruso, Irene, et al.
Publicado: (2022)

Role of Glucose-Lowering Medications in Erectile Dysfunction
por: Cignarelli, Angelo, et al.
Publicado: (2021)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Impaired Leptin Signalling in Obesity: Is Leptin a New Thermolipokine?
por: Genchi, Valentina Annamaria, et al.
Publicado: (2021)

Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity
por: Palma, Giuseppe, et al.
Publicado: (2022)

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
por: Marrano, Nicola, et al.
Publicado: (2021)

Insulin and Insulin Receptors in Adipose Tissue Development
por: Cignarelli, Angelo, et al.
Publicado: (2019)

Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
por: Genchi, V. A., et al.
Publicado: (2023)

The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor
por: D'Oria, Rossella, et al.
Publicado: (2020)

Effects of Extra Virgin Olive Oil Polyphenols on Beta-Cell Function and Survival
por: Marrano, Nicola, et al.
Publicado: (2021)

Diabetes in the Time of COVID-19: A Twitter-Based Sentiment Analysis
por: Cignarelli, Angelo, et al.
Publicado: (2020)

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
por: Caruso, Irene, et al.
Publicado: (2023)

Impact of Dysfunctional Adipose Tissue Depots on the Cardiovascular System
por: D’Oria, Rossella, et al.
Publicado: (2022)

Cross-Talk between PPARγ and Insulin Signaling and Modulation of Insulin Sensitivity
por: Leonardini, Anna, et al.
Publicado: (2009)

Effects of CPAP on Testosterone Levels in Patients With Obstructive Sleep Apnea: A Meta-Analysis Study
por: Cignarelli, Angelo, et al.
Publicado: (2019)

Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
por: Castellana, Marco, et al.
Publicado: (2020)

Type 2 Diabetes and Alzheimer’s Disease: The Emerging Role of Cellular Lipotoxicity
por: Marrano, Nicola, et al.
Publicado: (2023)

Adipose Tissue Dysfunction and Obesity-Related Male Hypogonadism
por: Genchi, Valentina Annamaria, et al.
Publicado: (2022)

Implicazioni cliniche extraglicemiche dell’insulino-resistenza
por: Caporusso, Mariangela, et al.
Publicado: (2022)

TNFα Signals via p66(Shc) to Induce E-Selectin, Promote Leukocyte Transmigration and Enhance Permeability in Human Endothelial Cells
por: Laviola, Luigi, et al.
Publicado: (2013)

Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis
por: Garruti, Gabriella, et al.
Publicado: (2023)

Differences in Gene Expression and Cytokine Release Profiles Highlight the Heterogeneity of Distinct Subsets of Adipose Tissue-Derived Stem Cells in the Subcutaneous and Visceral Adipose Tissue in Humans
por: Perrini, Sebastio, et al.
Publicado: (2013)

A telemedicine-based approach with real-time transmission of blood glucose data improves metabolic control in insulin-treated diabetes: the DIAMONDS randomized clinical trial
por: Di Molfetta, S., et al.
Publicado: (2022)

Postprandial glucose and HbA1c are associated with severity of obstructive sleep apnoea in non-diabetic obese subjects
por: Cignarelli, A., et al.
Publicado: (2021)

Adipose Tissue Secretion Pattern Influences β-Cell Wellness in the Transition from Obesity to Type 2 Diabetes
por: Biondi, Giuseppina, et al.
Publicado: (2022)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
por: Baviera, Marta, et al.
Publicado: (2022)

Removal of Duodenum Elicits GLP-1 Secretion
por: Muscogiuri, Giovanna, et al.
Publicado: (2013)

Influence of CAG Repeat Polymorphism on the Targets of Testosterone Action
por: Tirabassi, Giacomo, et al.
Publicado: (2015)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
por: Giorgino, Francesco, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rhsr297ukmtssmciecq4rmd9gs